Exploring Rab 32 Gene Variations in Leprosy Patients
Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients and Its Relation to Multiple Drug Therapy: Randomized Clinical Trial
NA · South Valley University · NCT06819449
This study is trying to see if differences in a specific gene can help predict how leprosy patients will respond to treatment and how severe their disease might be.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 5 Years to 60 Years |
| Sex | All |
| Sponsor | South Valley University (other) |
| Locations | 1 site (Qina) |
| Trial ID | NCT06819449 on ClinicalTrials.gov |
What this trial studies
This study investigates the role of Rab 32 gene polymorphisms as a potential prognostic factor in patients suffering from leprosy, caused by the Mycobacterium leprae bacterium. It aims to understand how these genetic variations may influence the disease's progression and response to treatment. The study will involve patients with confirmed leprosy, who will be treated with standard multi-drug therapy, including dapsone. By analyzing the genetic profiles of these patients, researchers hope to identify markers that could predict treatment outcomes and disease severity.
Who should consider this trial
Good fit: Ideal candidates for this study are patients of both sexes with a positive slit skin smear for Mycobacterium leprae.
Not a fit: Patients with hypersensitivity to sulfa drugs, clofazimine, or rifampicin, as well as pregnant or lactating women, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic tools for leprosy patients, allowing for more personalized treatment strategies.
How similar studies have performed: While the specific approach of examining Rab 32 gene polymorphisms in leprosy is novel, similar genetic studies in other infectious diseases have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients of both sexes with positive slit skin smear for m.leprae . Exclusion Criteria: * Contraindications to Multi drug therapy : * Patients with hypersensitivity to sulfa . * Patients with hypersensitivity to clofazimine or rifampcin. * pregnant or lactating women.
Where this trial is running
Qina
- Qina University hospital, South Valley University Hospital — Qina, Egypt (RECRUITING)
Study contacts
- Study coordinator: Lydia Atef Nassief, MSc
- Email: lydiaatef67@gmail.com
- Phone: +201289416276
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Leprosy, Mycobacterium Leprae Infection